amikacin has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babapoor, E; Dezfulian, M; Rahmati, M | 1 |
1 other study(ies) available for amikacin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Amikacin-loaded niosome nanoparticles improve amikacin activity against antibiotic-resistant Klebsiella pneumoniae strains.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cholesterol; COVID-19; Humans; Klebsiella pneumoniae; Lipids; Liposomes; Microbial Sensitivity Tests; Nanoparticles; Polysorbates; RNA, Messenger; SARS-CoV-2; Surface-Active Agents | 2022 |